The VIVACE Electrosurgical System is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles. This Vivace Electrosurgical System is intended for use with Skin Type I to Skin Type V.

Device Description

The VIVACE Electrosurgical System is comprised of the following components: the system main body of the device which consists of the LCD touch screen control panel, the high frequency generating output section (main P.C.B board or RF Generator), and the power supply component, the Switching Power Supply (SMPS). The accessories to the device include the handpiece with disposable micro-need le cartridge (electrode) insertion, and foot switch. Radio frequency current (RF energy) is delivered from the RF Generator, through the handpiece and electrode tip into the target tissue. The hand piece being held at right angles, the tip is placed in light contact with the epidermis. As RF energy passes through the skin, it generates an electro thermal reaction, which is capable of coagulating (causing minor dermal damage) the tissue. The bi-polar RF energy is delivered between independent adjacent electrode pairs (total 36 needle electrode, 6 x 6 array insertion). The RF generator, hand piece are not disposable. Each disposable micro-needle cartridge (electrode) is supplied sterile and is for single patient use only and cannot be resterilized.

AI/ML Overview

Here's a breakdown of the acceptance criteria and study information for the VIVACE Electrosurgical System based on the provided document:

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria	Reported Device Performance
Clinical Efficacy (Wrinkle Improvement)	Among 3 blinded evaluators, by 2/3 evaluator agreement (≥ 1 point change) criteria, 17 out of 28 (60.7%) subjects had one point improvement at 90-day follow-up using the Fitzpatrick Wrinkle and Elastosis Scale. The device showed moderate, but positive improvement in wrinkle severity and elastosis damage.
Clinical Safety (Adverse Events)	Adverse Events that occurred in greater than 5% of subjects were Erythema (77.42%), Edema (19.35%), Edema (16.13%), and Sensitivity (6.45%). Adverse event cases decreased with each re-treatment phase for all AE types and were resolved within 24 hours. Overall adverse event rates were highest at the first treatment cycle (70.97%) and decreased significantly by the third treatment cycle (6.45%).
Pain Level	Most patients felt less pain overall through 3 treatment cycles. At the 1st treatment cycle, 9/28 (32%) experienced pain at level 1-3, 12/28 (43%) at level 4-6, and 7/28 (25%) at level 7-10. During the 3rd treatment cycle, 15/28 (53%) reported pain at levels 1-3, 12/28 (43%) at levels 4-6, and 1/28 (3.5%) at levels over 8.
Electrical Safety	Electrical safety tests were completed. (Specific acceptance thresholds are not provided in the summary).
Electromagnetic Compatibility	Electromagnetic compatibility tests were completed. (Specific acceptance thresholds are not provided in the summary).
Sterility	Micro-needle cartridge is supplied sterile and sterility conforms to a Sterility Assurance Level (SAL) of 10⁻⁶.
Biocompatibility	Biocompatibility studies of all patient contact materials were performed in accordance with ISO 10993-1.
No new safety/effectiveness issues	There are no new safety or effectiveness issues related to this device.
Overall Safety and Effectiveness	The VIVACE Electrosurgical System is safe and effective for its intended use. The clinical study demonstrates that the VIVACE functions as intended with no significant impact on the safety and effectiveness profile of the device.

2. Sample Size Used for the Test Set and Data Provenance

Sample Size (Clinical Study): 31 participants were enrolled, with 28 subjects completing all three sessions and included in the final study analysis.
Data Provenance: The study was a "31 patient US study," indicating the data was collected in the United States and was prospective as it involved tracking subjects over time after treatment.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications

Number of Experts: Three, blinded, independent licensed physicians.
Qualifications: "Licensed physicians" is the only qualification explicitly stated. No specific experience level (e.g., "radiologist with 10 years of experience") is provided.

4. Adjudication Method for the Test Set

Adjudication Method: "By 2/3 evaluator agreement (≥ 1 point change) criteria." This means that for a subject to be considered to have improved, at least two out of the three blinded evaluators had to agree on at least a one-point improvement on the score.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, an MRMC comparative effectiveness study involving human readers with and without AI assistance was not reported in this summary. The study focused on the device's standalone clinical efficacy.

6. Standalone (Algorithm Only) Performance Study

This device is an electrosurgical system, not an AI algorithm. Therefore, a standalone (algorithm only without human-in-the-loop performance) study in the context of AI is not applicable. The clinical study described evaluates the device's performance when used by clinicians.

7. Type of Ground Truth Used

Clinical Ground Truth: Expert consensus of three blinded physicians using a validated clinical scoring methodology (9-point Fitzpatrick Wrinkle and Elastosis Scale).

8. Sample Size for the Training Set

Not Applicable / Not Provided: This device is a medical instrument (electrosurgical system), not an AI algorithm that requires a training set in the typical sense. The summary describes a clinical study to validate the device's performance, not to train a predictive model.

9. How the Ground Truth for the Training Set Was Established

Not Applicable / Not Provided: As in point 8, this is not an AI algorithm with a training set. The "ground truth" (clinical outcomes) described in the performance section was established by expert evaluation.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features the department's name in a circular arrangement around a stylized image of three human profiles. The profiles are stacked on top of each other and are connected by a flowing line that resembles a ribbon or a wave.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

January 15, 2016

Sung Hwan E&B Company, Ltd % Mr. Kachi Enyinna 510K Technology Group, LLC 263 Huntington Avenue, #332 Boston, Massachusetts 02115

Re: K150409

Trade/Device Name: VIVACE Electrosurgical System Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: Class II Product Code: OUH Dated: November 30, 2015 Received: December 3, 2015

Dear Mr. Enyinna:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{1}------------------------------------------------

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Jennifer R. Stevenson -S

For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known) K150409

Device Name

VIVACE Electrosurgical System

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
☒Prescription Use (Part 21 CFR 801 Subpart D) ☐Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services

Food and Drug Administration

Office of Chief Information Officer

Paperwork Reduction Act (PRA) Staff

PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Sung Hwan E&B Co., Ltd.

Vivace Electrosurgical System 510(k) Notification

510(k) Summary

This 510(k) Summary is in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content of this 510(k) summary is provided in conformance with 21 CFR Part 807.92.

I. Sponsor's Information

Name:	Sung Hwan E&B Co., Ltd.
Address:	Suite #502, SK Techno Bldg16-4 Sung Su-Dong 1 GaSung Dong Ku, Seoul Korea
Phone:	82-2-466-0010
Fax:	82-2-466-5473
Contact Person:	Sun Young KangTel: 82-2-466-0010Fax: 82-2-466-5473Email: ksy66820@naver.com
Official Correspondent:	Kachi Enyinna, MSPrincipal Consultant510K Technology Group, LLC263 Huntington Avenue, Suite 332Boston, MA 02115(240) 994-4242
Date Prepared:	January 6, 2016
II. Device Name
Trade Name:	VIVACE
Common Name:	Electrosurgical System and Accessories
Classification Name:	Electrosurgical Cutting and Coagulation device andAccessories
Classification Number:	21 CFR 878.4400
Product Code:	OUH
Classification Panel:	General and Plastic Surgery

III. Predicate Device

The VIVACE Electrosurgical System is substantially equivalent to the INFINI Radiofrequency System (K121481).

{4}------------------------------------------------

IV. Intended Use

V. Device Description

	Electrical voltage and frequency	AC 230V 50/60 Hz
	Power conception	40 VA
	Maximum output current	62mA ± 20% (load resistance500Ω
	Maximum output voltage	134V ± 20% (load resistance500Ω
	Accuracy of the output frequency	1 MHz
MicroneedleCartridge	ElectrodeExposedlength	36 each, 6 x 6 array0.5 ~ 3.5mm (0.1mm increments)
	Outerdiameter	∅0.3mm
Weight
Dimension		(W)380mm x (L)340mm x(H)1200mm

VI. Technical Specifications

{5}------------------------------------------------

VII. Performance Data

Electrical safety test, Electromagnetic compatibility test, Sterility, and Biocompatibility testing were completed to demonstrate the safety and performance of the VIVACE Electrosurgical System.

Tests were performed on the Vivace Electrosrugical System and its sterile disposable single use micro-needle cartridge. The biological safety of the device has been demonstrated through biocompatibility studies of all patient contact materials in accordance with the standards outlined in IS010993-1

Results of the clinical testing demonstrated that the VIVACE Electrosurgical System is safe and effective for its intended use. The micro-need le cartridge is supplied sterile and sterility conforms to a Sterility Assurance Level (SAL) of 10° . The supplied Instructions for Use provide the user with the applicable warnings and cautions during use. There are no new safety or effectiveness issues related to this device.

VIII. Clinical Summary

The study had 31 participants with 28 subjects completing all three sessions and are included in the final study analysis. The data were evaluated against baseline at 30 days. 60 days and 90 days by three. blinded, independent licensed physicians using the 9-point Fitzpatrick Wrinkle and Elastosis scale scoring methodology for the peri-oral and periorbital regions. The scores showed improvement over the 90 day period after treatments. Among the 3 blinded evaluators, by 2/3 evaluator agreement (≥ 1 point change) criteria, 17 out of 28 (60.7%) subjects had one point improvement at 90 day follow up.

Adverse Events that occurred in greater than 5% of the subjects were Erythema (77.42%), Edema (19.35%), Edema (16.13%), and Sensitivity (6.45%). Adverse event cases decreased with each re-treatment phase for all AE types and were resolved within 24 hours. Overall adverse event rates were highest at the first treatment cycle, decreasing by a third after the second treatment and with little to no AEs reported after the third and final treatment (from 70.97% at treatment cycle 1 down to 6.45% at treatment cycle 3). Across treatments, each AE consistently decreased after the first, second and third (final) treatment cycles for every AE.

{6}------------------------------------------------

Sung Hwan E&B Co., Ltd.

Vivace Electrosurgical System 510(k) Notification

Most of the patients felt less pain overall through 3 treatment cycles. At 1st treatment cycle, for the peri-orbital wrinkle area, 9/28 subjects experienced pain at level 1-3 (32%) range, 12/28 at level 4 to 6 (43%) range, and 7/28 at level 7 to 10 (25%) range. During 3rd treatment cycle, 15/28 subjects reported experiencing pain at levels 1-3(53%), 12/28 at levels 4 to 6 (43%), and 1/28 at levels over 8 (3.5%). We hypothesize that the decrease in pain may be related to tissue coagulation and increased dermal thickness from initial exposure to RF energy treatment. During the 7-10 day interval, histological changes in the dermis may affect sensitivity during follow up treatment cycles with increase to RF energy.

The data shows gradual wrinkle class improvement at 90 days. The scores and change in wrinkle class demonstrate improvement in rhytids and in solar elastosis. The independent blinded evaluations support post treatment efficacy based on the Fitzpatrick Wrinkle Scores. All studied parameters suggest a favorable treatment profile of the VIVACE device to reduce wrinkles in the peri-orbital and peri-oral regions. The device showed moderate, but positive improvement in wrinkle severity and elastosis damage.

IX. Conclusion

The intended use of the VIVACE Electrosurgical System is substantially equivalent to the predicate device in intended use, design and RF technology. The clinical study demonstrates that the VIVACE functions as intended with no significant impact on the safety and effectiveness profile of the device for the treatment of facial wrinkles.

Data to support substantial equivalence to the predicate device was generated in a clinical study. The clinical study was designed to demonstrate the Vivace device is safe and effective for the treatment of facial wrinkles. Clinical data from a 31 patient US study using a validated scale, Fitzpatrick Wrinkle Severity Scale, supported substantial equivalence of the VIVACE to the predicate device for the percutaneous treatment of facial wrinkles in peri-oral and peri-orbital regions.

Regulation Number and Section

§ 878.4400 Electrosurgical cutting and coagulation device and accessories.

(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.